Edge Wealth Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Edge Wealth Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-4,175	Closed	-$68K	–	478
2021 Q4	$68K	Hold	4,175	–	–	0.01%	156
2021 Q3	$116K	Hold	4,175	–	–	0.02%	118
2021 Q2	$124K	Hold	4,175	–	–	0.03%	120
2021 Q1	$117K	Hold	4,175	–	–	0.02%	125
2020 Q4	$120K	Hold	4,175	–	–	0.03%	112
2020 Q3	$105K	Sell	4,175 -575	-12%	-$15.1K	0.02%	144
2020 Q2	$116K	Hold	4,750	–	–	0.02%	184
2020 Q1	$70K	Hold	4,750	–	–	0.02%	205
2019 Q4	$77K	Buy	4,750 +1,500	+46%	+$23.3K	0.02%	222
2019 Q3	$42K	Hold	3,250	–	–	0.01%	266
2019 Q2	$42K	Hold	3,250	–	–	0.01%	275
2019 Q1	$51K	Buy	3,250 +2,750	+550%	+$47.7K	0.01%	241
2018 Q4	$10K	Hold	500	–	–	﹤0.01%	405
2018 Q3	$12K	Hold	500	–	–	﹤0.01%	417
2018 Q2	$14K	Hold	500	–	–	﹤0.01%	388
2018 Q1	$15K	Buy	+500	New	+$16.1K	﹤0.01%	340

Other funds holding RVNC

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Edge Wealth Management's RVNC Position: Q1 2022 in Review

Edge Wealth Management sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2022, closing a stake of 4,175 shares — an estimated $68K sold.

Edge Wealth Management first reported a position in RVNC in Q1 2018 and held it in 16 quarters. The position peaked at $124K in Q2 2021. 156 funds tracked by Wall St. Rank hold RVNC as of Q1 2022.

Edge Wealth Management reported no remaining Revance Therapeutics, Inc. position as of Q1 2022 after selling out during the quarter.
Edge Wealth Management sold 4,175 Revance Therapeutics, Inc. shares in Q1 2022, an estimated $68K.
Edge Wealth Management first reported a position in Revance Therapeutics, Inc. in Q1 2018 and held it in 16 quarters.
Edge Wealth Management's Revance Therapeutics, Inc. position peaked at $124K in Q2 2021.
156 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2022.

Based on Edge Wealth Management's 13F filing for Q1 2022, filed 14 Apr 2022.